人巨噬细胞与Tca8113细胞融合瘤苗的制备及体外抗肿瘤效应

Anti-tumor immune response in vitro induced by fusion of Tca8113 cells with macrophages

目的探讨巨噬细胞融合瘤苗在舌癌免疫治疗中的应用。方法利用人巨噬细胞与Tca8113细胞融合,通过磁微珠筛选出融合细胞(FC)并扩大培养,观察FC的生物学特性及其体外诱导抗肿瘤特异性免疫的能力。结果FC瘤苗的生长低于其亲本Tca8113细胞,流式细胞仪检测融合细胞的主要组织相容性抗原(MHC)Ⅰ、Ⅱ类分子的表达高于Tca8113,能有效刺激混合淋巴细胞反应(MLR),并能在体外诱导淋巴细胞抑制肿瘤细胞Tca8113的生长。结论融合细胞瘤苗能显著提高亲源舌癌细胞Tca8113的免疫原性,提示融合细胞瘤苗是一种新的抗肿瘤免疫治疗方法,可作为个体化肿瘤疫苗的新方案。

Objective To evaluate the therapeutic effectiveness of fusion tumor vaccine in tongue cancer treatment. Methods Human macrophages fused with human tongue carcinoma cell line Tca8113 cell. The fusion cells were selected by magnetic cell sorting (MACS) and cultured. The biological properties of fusion cells and anti-tumor immune response in vitro induced by fusions were observed. Results In contrast to Tca8113, the fused cells grew significantly slow in vitro. The expression of MHC Ⅰ、Ⅱ antigen of the fusion cells which was detected by flow cytometry(FCM) was higher than that of Tca8113. The fused cells significantly increased the proliferation of mixed lymphocyte and induced thire cytotoxicity on parental Tca8113.Conclusions The fusion tumor vaccine of macrophages and OSCC cells increase in vitro immunogenicity significantly. This indicates that fusion tumor vaccine could be a new method of anti-tumor immunotherapy, which has important potentials for effective individualized human OSCC vaccine.